In season 2, episode 3 of Targeted Talks, Jason Luke, MD, a medical oncologist and director of the Center for Therapeutics at UPMC Hillman Cancer Center, and an associate professor of medicine, leads a discussion with Sandip Patel, MD, a medical oncologist and associate professor of medicine at the University of California San Diego Health, about the present and future of immunotherapy in cancer.
Many of the available immunotherapy agents, specifically anti–PD-L1 and anti–CTLA-4–directed therapies, were first used for cutaneous and thoracic tumors. A newer option for patients after progression is T cell immunoglobulin and ITIM domain (TIGIT). In the
